Antiretroviral drugs

Current Opinion in Pharmacology

Volumn 10, Issue 5, 2010, Pages 507-515

  De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL RESISTANCE; DRUG EFFICACY; DRUG INDICATION; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG USE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; LICENSING; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS INHIBITION; VIRUS MUTATION; VIRUS STRAIN;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HIV INFECTIONS; HUMANS;

EID: 77956647281     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2010.04.011     Document Type: Review

References (45)

1. Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res 2010, 85:1-18.
2. De Clercq E. In search of a selective therapy of viral infections. Antiviral Res 2010, 85:19-24.
3. Martin J.C., Hitchcock M.J.M., De Clercq E., Prusoff W.H. Early nucleoside reverse transcriptase inhibitors for the treatment of HIV: a brief history of stavudine (D4T) and its comparison with other dideoxynucleosides. Antiviral Res 2010, 85:34-38.
4. Cihlar T., Ray A.S. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. Antiviral Res 2010, 85:39-58.
5. Wensing A.M., van Maarseveen N.M., Nijhuis M. Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance. Antiviral Res 2010, 85:59-74.
6. de Béthune M.P. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). Antiviral Res 2010, 85:75-90.
7. Tilton J.C., Doms R.W. Entry inhibitors in the treatment of HIV-1 infection. Antiviral Res 2010, 85:91-100.
8. McColl D.J., Chen X. Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy. Antiviral Res 2010, 85:101-118.
9. Adamson C.S., Freed E.O. Novel approaches to inhibiting HIV-1 replication. Antiviral Res 2010, 85:119-141.
10. Dickinson L., Khoo S., Back D. Pharmacokinetics and drug-drug interactions of antiretrovirals: an update. Antiviral Res 2010, 85:176-189.
11. Hawkins T. Understanding and managing the adverse effects of antiretroviral therapy. Antiviral Res 2010, 85:201-209.
12. Menéndez-Arias L. Molecular basis of human immunodeficiency virus drug resistance: an update. Antiviral Res 2010, 85:210-231.
13. Mitsuya H., Weinhold K.J., Furman P.A., St Clair M.H., Lehrman S.N., Gallo R.C., Bolognesi D., Barry D.W., Broder S. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA 1985, 82:7096-7100.
14. Mitsuya H., Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. Proc Natl Acad Sci USA 1986, 83:1911-1915.
15. Mitsuya H., Popovic M., Yarchoan R., Matsushita S., Gallo R.C., Broder S. Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. Science 1984, 226:172-174.
16. De Clercq E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents 2009, 33:307-320.
17. De Clercq E. The history of antiretrovirals: key discoveries over the past 25 years. Rev Med Virol 2009, 19:287-299.
18. De Clercq E: Tenofovir disoproxil fumarate (TDF): discovery and clinical development. In Antiviral Drugs: Biology, Chemistry, Clinic. Edited by Kazmierski WM. John Wiley Sons Inc., Hoboken, NJ; 2010:in press.
19. Shimura K., Kodama E.N. Elvitegravir: a new HIV integrase inhibitor. Antiviral Chem Chemother 2009, 20:79-85.
20. Azijn H., Tirry I., Vingerhoets J., de Béthune M.P., Kraus G., Boven K., Jochmans D., Van Craenenbroeck E., Picchio G., Rimsky L.T. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother 2010, 54:718-727.
21. De Clercq E: From TIBO to rilpivirine: the chronicle of the discovery of the ideal non-nucleoside reverse transcriptase inhibitor (NNRTI). In Antiviral Drug Strategies. Edited by De Clercq E. Wiley-VCH Verlag, Weinheim, Germany; 2010:in press.
22. Summa V., Petrocchi A., Bonelli F., Crescenzi B., Donghi M., Ferrara M., Fiore F., Gardelli C., Gonzalez Paz O., Hazuda D.J., et al. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J Med Chem 2008, 51:5843-5855.
23. Croxtall J.D., Keam S.J. Raltegravir: a review of its use in the management of HIV infection in treatment-experienced patients. Drugs 2009, 69:1059-1075.
24. Steigbigel R.T., Cooper D.A., Kumar P.N., Eron J.E., Schechter M., Markowitz M., Loutfy M.R., Lennox J.L., Gatell J.M., Rockstroh J.K., et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008, 359:339-354.
25. Cooper D.A., Steigbigel R.T., Gatell J.M., Rockstroh J.K., Katlama C., Yeni P., Lazzarin A., Clotet B., Kumar P.N., Eron J.E., et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008, 359:355-365.
26. Grant P.M., Palmer S., Bendavid E., Talbot A., Slamowitz D.C., Cain P., Kobayashi S.S., Balamane M., Zolopa A.R. Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of life. J Clin Virol 2009, 46:305-308.
27. Lennox J.L., DeJesus E., Lazzarin A., Pollard R.B., Madruga J.V., Berger D.S., Zhao J., Xu X., Williams-Diaz A., Rodgers A.J., et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009, 374:796-806.
28. De Clercq E. A new drug combination therapy for treatment-naïve patients with HIV-1 infection, consisting of Raltegravir, emtricitabine and tenofovir disoproxil fumarate. Expert Opin Pharmacother 2009, 10:2935-2937.
29. Marcelin A.G., Ceccherini-Silberstein F., Perno C.F., Calvez V. Resistance to novel drug classes. Curr Opin HIV AIDS 2009, 4:531-537.
30. Koelsch K.K., Cooper D.A. Integrase inhibitors in salvage therapy regimens for HIV-1 infection. Curr Opin HIV AIDS 2009, 4:518-523.
31. Malet I., Delelis O., Valantin M.A., Montes B., Soulie C., Wirden M., Tchertanov L., Peytavin G., Reynes J., Mouscadet J.F., et al. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother 2008, 52:1351-1358.
32. Wirden M., Simon A., Schneider L., Tubiana R., Malet I., Ait-Mohand H., Peytavin G., Katlama C., Calvez V., Marcelin A.G. Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug. J Antimicrob Chemother 2009, 64:1087-1090.
33. Quercia R., Dam E., Perez-Bercoff D., Clavel F. Selective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes. J Virol 2009, 83:10245-10249.
34. Baldanti F., Paolucci S., Gulminetti R., Brandolini M., Barbarini G., Maserati R. Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens. J Med Virol 2010, 82:116-122.
35. Sichtig N., Sierra S., Kaiser R., Däumer M., Reuter S., Schülter E., Altmann A., Fätkenheuer G., Dittmer U., Pfister H., Esser S. Evolution of raltegravir resistance during therapy. J Antimicrob Chemother 2009, 64:25-32.
36. Delelis O., Thierry S., Subra F., Simon F., Malet I., Alloui C., Sayon S., Calvez V., Deprez E., Marcelin A.G., et al. Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo. Antimicrob Agents Chemother 2010, 54:491-501.
37. Goethals O., Clayton R., Van Ginderen M., Vereycken I., Wagemans E., Geluykens P., Dockx K., Strijbos R., Smits V., Vos A., et al. Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol 2008, 82:10366-10374.
38. Hughes C.A., Robinson L., Tseng A., MacArthur R.D. New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir. Expert Opin Pharmacother 2009, 10:2445-2466.
39. Brown K.C., Paul S., Kashuba A.D. Drug interactions with new and investigational antiretrovirals. Clin Pharmacokinet 2009, 48:211-241.
40. Wenning L.A., Friedman E.J., Kost J.T., Breidinger S.A., Stek J.E., Lasseter K.C., Gottesdiener K.M., Chen J., Teppler H., Wagner J.A., et al. Lack of a significant drug interaction between raltegravir and tenofovir. Antimicrob Agents Chemother 2008, 52:3253-3258.
41. Hanley W.D., Wenning L.A., Moreau A., Kost J.T., Mangin E., Shamp T., Stone J.A., Gottesdiener K.M., Wagner J.A., Iwamoto M. Effect of tipranavir-ritonavir on pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2009, 53:2752-2755.
42. Imaz A., del Saz S.V., Ribas M.A., Curran A., Caballero E., Falcó V., Crespo M., Ocaña I., Diaz M., de Gopegui E.R., et al. Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection. J Acquir Immune Defic Syndr 2009, 52:382-386.
43. Thuret I., Chaix M.L., Tamalet C., Reliquet V., Firtion G., Tricoire J., Rabaud C., Frange P., Aumaître H., Blanche S. Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus. AIDS 2009, 23:2364-2366.
44. Piot P., Kazatchkine M., Dybul M., Lob-Levyt J. AIDS: lessons learnt and myths dispelled. Lancet 2009, 374:260-263.
45. Richman D.D., Margolis D.M., Delaney M., Greene W.C., Hazuda D., Pomerantz R.J. The challenge of finding a cure for HIV infection. Science 2009, 323:1304-1307.